TLP
TBPH icon

Tri Locum Partners’s Theravance Biopharma TBPH Stock Holding History

Tri Locum Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-129,192
Closed -$956K – 52
2021
Q3 		$956K Buy
+129,192
New +$1.45M 0.38% 27
2021
Q1 		– Sell
-49,373
Closed -$877K – 72
2020
Q4 		$877K Buy
+49,373
New +$886K 0.32% 37

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Tri Locum Partners's TBPH Position: Q4 2021 in Review

Tri Locum Partners sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 129,192 shares — an estimated $956K sold.

Tri Locum Partners first reported a position in TBPH in Q4 2020 and held it in 2 quarters. The position peaked at $956K in Q3 2021. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

  • Tri Locum Partners reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
  • Tri Locum Partners sold 129,192 Theravance Biopharma shares in Q4 2021, an estimated $956K.
  • Tri Locum Partners first reported a position in Theravance Biopharma in Q4 2020 and held it in 2 quarters.
  • Tri Locum Partners's Theravance Biopharma position peaked at $956K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Tri Locum Partners's 13F filing for Q4 2021, filed 14 Feb 2022.